AVDL
Closed
Avadel Pharmaceuticals Plc
8.81
-0.04 (-0.45%)
Last Update: 01 Jul 2025 23:14:00
Yesterday: 8.85
Day's Range: 8.5194 - 8.91
Send
sign up or login to leave a comment!
When Written:
9.16
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company that develops and commercializes pharmaceutical products for various medical conditions. The company is headquartered in Dublin, Ireland, and has operations in the United States. Avadel Pharmaceuticals focuses on developing and commercializing drugs for the central nervous system, including insomnia and Parkinson's disease.
The company's product portfolio includes a range of branded and generic pharmaceutical products, including nocturnal enuresis treatment, migraine treatment, and Parkinson's disease treatment. Avadel Pharmaceuticals has a strong pipeline of products in development, including a novel formulation of sodium oxybate for the treatment of narcolepsy.
Avadel Pharmaceuticals was founded in 2015 and is publicly traded on the NASDAQ stock exchange under the ticker symbol AVDL. The company has a global workforce of approximately 200 employees and has a strong commitment to research and development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's product portfolio includes a range of branded and generic pharmaceutical products, including nocturnal enuresis treatment, migraine treatment, and Parkinson's disease treatment. Avadel Pharmaceuticals has a strong pipeline of products in development, including a novel formulation of sodium oxybate for the treatment of narcolepsy.
Avadel Pharmaceuticals was founded in 2015 and is publicly traded on the NASDAQ stock exchange under the ticker symbol AVDL. The company has a global workforce of approximately 200 employees and has a strong commitment to research and development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








